Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids
Laparoscopic Ultrasound-Guided Laparoscopic Myomectomy for Multiple Uterine Fibroids: A Prospective Randomized Controlled Trial
This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.
The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.
The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.
Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.
研究概览
地位
条件
详细说明
Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.
Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.
Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Xiali Xiong
- 电话号码:+86-13520418824
- 邮箱:xiongxiali2009@163.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100024
- Beijing Chao Yang Hospital, Capital Medical University
-
接触:
- Xiali Xiong
- 电话号码:+86-13520418824
- 邮箱:xiongxiali2009@163.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
- Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
- Age 20 to 50 years and premenopausal, with or without future fertility plans.
- No contraindications to laparoscopic surgery.
Exclusion Criteria:
- Concomitant submucosal fibroids classified as FIGO types 0-2.
- Findings suspicious for malignancy on preoperative assessment.
- Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
- Known severe hepatic or renal dysfunction.
- Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
- Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
- Acute infection.
- Inability to sign the informed consent form.
- Known or suspected poor adherence that would prevent completion of the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Laparoscopic Ultrasound-Guided Myomectomy
Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal. |
During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety. |
|
有源比较器:Conventional Laparoscopic Myomectomy
Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. |
Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fibroid Removal Rate
大体时间:During surgery and within 3 months after surgery
|
For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100. |
During surgery and within 3 months after surgery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Operative Time
大体时间:During surgery
|
Duration of the surgical procedure, measured in minutes. |
During surgery
|
|
Residual Uterine Fibroid Rate
大体时间:3 months after surgery (+/- 14 days)
|
Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100. |
3 months after surgery (+/- 14 days)
|
|
Difference Between Removed and Preoperatively Identified Fibroid Counts
大体时间:Preoperative assessment and during surgery
|
For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging. |
Preoperative assessment and during surgery
|
|
Estimated Intraoperative Blood Loss
大体时间:During surgery
|
Estimated volume of blood lost during surgery, measured in milliliters. |
During surgery
|
|
Participants With Intraoperative Complications
大体时间:During surgery
|
Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury. |
During surgery
|
|
Participants With Postoperative Complications
大体时间:From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
|
Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits. |
From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
|
|
Postoperative Length of Hospital Stay
大体时间:Perioperative
|
Time from completion of surgery to hospital discharge, measured in days. |
Perioperative
|
|
Postoperative Pain Score
大体时间:2 and 6 hours after surgery
|
Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain. |
2 and 6 hours after surgery
|
|
Time to First Postoperative Ambulation
大体时间:Perioperative
|
Time from completion of surgery to first postoperative ambulation, measured in hours. |
Perioperative
|
|
Time to First Postoperative Flatus
大体时间:Perioperative
|
Time from completion of surgery to first passage of flatus, measured in hours. |
Perioperative
|
|
Duration of Postoperative Uterotonic Treatment
大体时间:Perioperative
|
Duration of postoperative uterotonic medication use, measured in hours. |
Perioperative
|
|
Time to Postoperative Drain Removal
大体时间:Perioperative
|
Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed. |
Perioperative
|
|
Participants With Postoperative Urinary Dysfunction
大体时间:1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit. |
1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
|
Participants With Postoperative Bowel Dysfunction
大体时间:1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit. |
1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
|
Change From Baseline in Female Sexual Function Index Score
大体时间:Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function. |
Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
|
Change From Baseline in Oswestry Disability Index Score
大体时间:Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability. |
Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
|
Change From Baseline in Zung Self-Rating Anxiety Scale Score
大体时间:Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety. |
Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
|
15-Item Quality of Recovery Questionnaire Score
大体时间:Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated. |
Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2026-sci-844-1
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
There is no plan to share de-identified individual participant data with researchers outside the study team.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.